Press room | News

Jan 31, 2017

Heptares Enters a New Research Collaboration under its "ORBIT" Initiative with the University of Cambridge

Dec 8, 2016

Heptares Scientists Solve Structure of CCR9 Chemokine Receptor offering Unique Opportunity to Apply Structure-Based Design across Chemokine Receptor Family

Nov 30, 2016

Heptares to Acquire G7 Therapeutics to Extend Leadership in GPCR-Focused Drug Discovery and Development

Nov 10, 2016

Jitsubo and Heptares Therapeutics to develop novel GPCR-targeting peptide candidates for severe gastro-intestinal disorders

Oct 7, 2016

Heptares wins Best Established Biotech Company Award at OBN Annual Awards 2016

Jul 6, 2016

Initiation of Phase 1 Clinical Study with Novel Immuno-Oncology Candidate Triggers US$10 Million Milestone Payment from AstraZeneca

Jun 29, 2016

Heptares and leadXpro Enter Collaboration on Powerful New Approaches to GPCR Structure Determination for Drug Discovery

May 26, 2016

Hart-Scott-Rodino Clearance for Global Collaboration between its Subsidiary Heptares Therapeutics and Allergan

Apr 28, 2016

Heptares CSO and Co-founder - Dr Fiona Marshall - Elected as a Fellow of The Academy of Medical Sciences

Apr 25, 2016

Heptares Scientists Solve Structures of GLP-1 and Glucagon Receptors enabling Structure-Based Design for Metabolic Disease

Apr 18, 2016

Heptares and Kymab enter Strategic Collaboration to Discover, Develop and Commercialise Novel Antibody Therapeutics

Apr 6, 2016

Allergan and Heptares Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer’s and Other Neurological Disorders

Apr 4, 2016

Heptares Joins Pharma Consortium Applying State-of-the-Art Cryo-Electron Microscopy to Advance Structure-Based Drug Discovery

Feb 10, 2016

Heptares Announces Positive Results from Phase 1b Clinical Trial with HTL9936, a First-In-Class Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Dementia and Schizophrenia

Feb 2, 2016

Heptares Launches “ORBIT” Initiative - A New Collaborative Drug R&D Programme for Industry and Academia Focused on G Protein-Coupled Receptors (GPCRs)

Back to top

Other News

© 2012-2017 Heptares Therapeutics